- LOGIN
- MemberShip
- 2026-04-17 00:26:13
- Policy
- KAPO demands MFDS to swiftly approve Lutathera
- by Lee, Jeong-Hwan May 13, 2020 05:54am
- A patient group once again urged for a prompt approval review on neuroendocrine tumor treatment Lutathera (lutetium Lu 177 dotatate). The group demanded the Korean government to take action fast for the patients with neuroendocrine tumor in agony with inevitable overseas treatment and burdensome pharmaceutical expense amid COVID-19 pandemic. On May 11, Korea Alliance of Patients Organization (KAPO) held a press conference in front of the Ministry of Food and Drug Safety (MFDS) headquarter office in Osong and insisted the government to urgently take necessary action. KAPO officials explained currently about 100 patients with neuroendocrine tumor in Korea have been traveling to Malaysia to get access to radiopharmaceutical injections containing similar substance as Lutathera from 2018. The organization claimed patients in France and the U.S., where Lutathera is accessible, pay approximately 26 million won per shot, and at least 140 million won for a single cycle with four injections. KAPO also stated MFDS has been neglecting on their duty as the ministry has not expedited the approval procedure on Lutathera, when the drug has been designated as an orphan drug to meet urgent medical needs. The patient organization explained Korea Orphan and Essential Drug Center (KOEDC), specially distributing the drug for emergency purpose for now, has exceptionally requested for insurance reimbursement to Health Insurance Review and Assessment Service (HIRA). Apparently, however, HIRA has been sluggish with the listing review due to the prospective financial burden and concern of multinational pharmaceutical companies abusing the system. Ultimately, they argued, it is up to MFDS to officially approve the marketing of Lutathera in Korea and HIRA to officially review the reimbursement to improve the state the patients are in. KAPO official stressed, “MFDS should approve Lutathera and stop neglecting patients in life-threatening situations and letting them suffer in series of overseas treatment and financial struggle,” and “Novartis should also closely cooperate with the government approval procedure.”
- Opinion
- [Reporter’s view] Yuhan's CEO Lee made a big decision
- by Lee, Seok-Jun May 13, 2020 05:54am
- Jung Hee Lee, Yuhan CEO, is due until March next year. This is due to the company's policy of having two consecutive terms in three years. It will end in March next year. since he started working in March 2015. Most CEOs make their performances within their tenure. This is because 'maximum performance since its founding' can be a 'decoration' for their career. However, CEO Jung Hee Lee does not care about performance. Last year's (0.84%) and the first quarter's (0.35%) operating margin were the lowest, but the technology fee, which is a positive factor in earnings, is divided as conservatively as possible. The recent business report confirms this trend. Yuhan extended the expiry date of LO’s upfront fee for three cases. This is different from the report of the third quarter of last year. LO’s upfront fee for Lazertinib (anti-cancer drugs) exported to Janssen ($30 million) has extended from 2020 to 2021. The upfront fee for non-alcoholic steatohepatitis treatment, (NASH) YH2574 ($38 million), licensed out to Beringer, was extended from 2020 to 2022. the upfront fee for NASH treatment, sold to Gilead was set to be until 2021. Previously, only the principle of split recognition was disclosed, and the end date was not disclosed. In short, Yuhan delayed the completion of unfront fee accounting until 2022. The intention is to secure a fixed profit by dividing the down payment by 2022. This is a big decision for CEO Lee. If all of the LO’s upfront fee were reflected within the term, better results were possible in terms of sales and operating profit. The LO’s upfront fee left by Lee can strengthen the next CEO. This is because fixed profits are the driving force for maintaining R&D continuity without compromising earnings. Yuhan has a tradition of competing for two vice presidents and choosing a president. Either Wook-je Jo, Vice President (Management Division) or Jong-hyun Park, Vice President (Pharmaceutical Business Division) is a strong candidate. For one of them, CEO Lee's management to prepare for the future can be a valuable asset.
- Policy
- Whanin, begins development of first generic for Fycompa
- by Lee, Tak-Sun May 13, 2020 05:54am
- Antiepileptic drug Fycompa by EisaiWhanin, for the first time as a domestic pharmaceutical company, started developing generics for antiepileptic drug Fycompa by Eisai. If the generic development proceeds smoothly, it is expected that it will be aprproved next year as soon as possible. The MFDS approved the bioequivalence test plan for 'Peranel 6mg' submitted by Whanin on the 8th. Peranel is an imaginary item that has not yet been approved, and is the same ingredient as Fycompa. The bioequivalence test is conducted for the purpose of securing equivalence by comparing the absorption rates of Peranel and Fycompa in 56 healthy adults. The test was designed to run through May next year. Anyway, application for permission is possible only in July of next year. This is because Fycompa's PMS will expire on July 9th next year. Generics can be applied for approval only after the PMS period of the original has ended. Since Fycompa's material patent is due to expire on October 13, 2023, it will take three years to get to the market. Whanin filed a decision to confirm the passive scope of the right to evade the crystalline form patent scheduled to expire on October 14, 2026 in February. Since Myungin Pharmaceutical also requested the relevant judgement, it is highly likely to develop generics along with Whanin. Fycompa is a selective non-competitive a new mechanism of epilepsy treatment that antagonizes the AMPA (α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid) receptor, and has been designated as a new drug for six years of reexamination (PMS) by the MFDS. In 2017, it was approved by the US FDA as a monotherapy for patients with epilepsy (epileptic) partial seizures over 12 years of age with or without secondary systemic seizures. Based on UBIST, last year's domestic prescription amount was ₩3.4 billion. It has the advantage of being convenient for epilepsy patients to use, especially once a day.
- Company
- Boryung, acquires domestic sales rights for Lilly's GemZar
- by Kim, Jin-Gu May 13, 2020 05:53am
- GemZarBoryung acquired the domestic right for the anticancer drug 'GemZar (Gemcitabine HCl)' held by Eli Lilly. Boryung announced on the 8th that it had signed a contract to transfer assets to Eli Lilly and Gemzar. Through this agreement, Boryung has all rights, including domestic rights and licenses of Gemzar. Boryung and Eli Lilly have been conducting 'Gemzar' co-promotion since 2015. Gemzar is widely used in pancreatic cancer, non-small cell lung cancer, bladder cancer, breast cancer, ovarian cancer, and biliary tract cancer. It is used alone or in combination therapy in primary and secondary treatment. As of last year, Gemzar's domestic sales totaled ₩14.2 billion (based on IMS). Boryung expects to strengthen its anticancer drug portfolio and maximize its market share and profit margin. Currently, Boryung has a high market share in the domestic anticancer drug market with Oxalitin (Oxaliplatin) and Genexol (Paclitaxel). As of the fourth quarter of last year, among domestic pharmaceutical companies, it ranked No. 1 in the market for anti-tumor drugs and immunomodulators. David A. Ricks, chief executive officer of Eli Lilly said "I hope this contract will help further improve the treatment performance of Korean cancer patients," Jae-Hyun Ahn, Boryung’s CEO, emphasized, "Boryung, which is building the best anti-cancer drug business in Korea, can strengthen the line-up of anti-cancer drugs and make more stable profits with this brand acquisition." He said, "In the future, we will strengthen our portfolio for the anti-cancer area as well as grow it as a representative business of Boryung through active investment such as open innovation."
- Company
- Itaewon club-linked COVID-19 threatens the industry
- by An, Kyung-Jin May 12, 2020 06:28am
- Seoul Square building in Jung-gu, Seoul The pharmaceutical industry is straining as the number of confirmed COVID-19 from Seoul Itaewon Club increases. Pharmaceutical companies in the Seoul Square building where COVID-19 confirmed patients visited Itaewon went into emergency telecommuting, and nearby pharmaceutical companies are also watching closely. According to the industry on the 11th, MSD Korea and Korea Mundipharma, who entered the Seoul Square building in Jung-gu, Seoul, entered an emergency telecommuting work on this day. This is due to the fact that an employee of Pernold Ricard Korea, a company that imports and distributes alcoholic beverages, was confirmed COVID-19 after a visit to the area near Itaewon in Seoul. Pernold Ricard Korea has an office on the 10th floor of Seoul Square. Seoul Square carried out quarantine of the entire building over the weekend and closed the 10th floor. The policy is not to close the entire building immediately, but to decide whether to close the building based on the results of the epidemiological investigation. On the 10th, MSD Korea and Korea Mundipharma, which had received notice of outbreak of confirmed cases, decided to carry out telecommuting for one day on the 11th and implemented their own quarantine. These companies have just started working in the office again, and are worried about whether they will return to work from home. MSD Korea has returned to normal business since the 27th of last month. The office workers work in the office, and the sales positions are made to be flexible depending on the workplace. Mundipharma has also applied its own guidelines to resume office activities as far as possible, while office workers go to the office three times a week from the end of April. Both companies are observing the trend for one day on the 11th and then deciding whether to go to work on the 12th through management meetings. Pharmaceutical companies that are not companies in Seoul Square are also watching carefully. Companies near the building with confirmed patients are more nervous. Beringer Ingelheim Korea is located in the Yonsei Severance Building, just next to Seoul Square. Employees of Boehringer Ingelheim are currently working normally on the 11th. Instead of switching to telecommuting right away, they are watching the occurrence trend of Itaewon's confirmed cases, including the news of the partial closure of the Seoul Square building. GSK and Janssen Korea, which have offices in Yongsan-gu, Seoul, do not have any changes in their attendance policy at this time. GSK ended telecommuting on the 6th and began to go to the office, and Janssen Korea has been applying for a policy to go to work every other day since the end of April. The two companies worked in telecommuting in February when a confirmed patient occurred in the office on the 16th floor of the same building. It is said that the situation is being watched by the spread of Itaewon club-linked COVID-19 and measures to close nearby buildings, but there are no plans to resume telecommuting at this time. The Yongsan LS Tower, where GSK and Janssen Korea resides, is located a 10-minute walk from the LG Uplus Yongsan office building, which was closed from the 11th. LG Uplus, a telecommunications company, shut down the Yongsan office building in Seoul for three days from the 11th, when an employee went to the Itaewon Club on the 10th and was confirmed positive. An official from the pharmaceutical industry said that the company attempted to resume sales marketing activities while switching to distancing in daily life, but concerns about COVID-19 re-proliferation are increasing. He said he was worried about going back to a month ago.
- Company
- Delay in choline alfoscerate reimbursement reevaluation
- by Kim, Jin-Gu May 12, 2020 06:28am
- Popular brand drugs with choline alfoscerate, Gliatamin and Gliatirin The sources speculate the Korean pharmaceutical industry’s hot potato, the reimbursement feasibility reevaluation on choline Alfoscerate would be postponed to the latter half of the year. On May 11, pharmaceutical industry sources reported the reimbursement reevaluation on choline alfoscerate has been pressed on since the last year’s National Assembly audit. Answering to Democratic Party Lawmaker Nam In-soon’s criticism on the underwhelming efficacy of choline alfoscerate during the audit session, the Minister of Health and Welfare Park Neung-hoo said, “The reevaluation would be promptly completed by June next year (2020).” From then on, the choline alfoscerate’s efficacy has been questioned increasingly. Ultimately, Health Insurance Review and Assessment Service (HIRA) convened a meeting for Drug Reimbursement Evaluation Committee (DREC) in last February addressing the plan to reevaluate the said substance. Seemingly, the reevaluation plan was close to being set on stone, but the committee meeting did not get to officially discuss over the subject, because it was addressed within ‘reporting agenda,’ not ‘deliberation agenda.’ Regardless, the table has turned as the novel coronavirus started spreading rapidly in Korea from March. As HIRA fully concentrated its capacity on COVID-19 treatment related work, other pharmaceutical affairs have been pushed aside indefinitely. After the February meeting, none of choline alfoscerate reevaluation related vis-à-vis meeting, expert consultation or pan-governmental collaboration have been progressed. Amid the pandemic, HIRA has confirmed ‘completing the reevaluation by June’ is practically impossible. On a phone interview with Daily Pharm, a HIRA official stated, “Due to the COVID-19 pandemic, it is true that [the discussion on the reevaluation] is getting delayed,” and “Since [the DREC meeting in] February, the government agency has not seen any progress on the matter. None of prospective scheduling has been set.” The official explained the agency would be unable to fully conclude the reevaluation within June as the actual time is running out, even if HIRA resumes the discussion immediately. For the reevaluation to rekindle the discussion and to proceed to reimbursement adjustment, the procedure would have to undergo consultation with industry officials, finalize the reevaluation decision, set detailed reimbursement standards, and have the Minister of Health and Welfare to notify the reimbursement standards. The overall procedure would take at least over a month. The pharmaceutical industry also gave a similar outlook. An industry official commented, “Technically, the government’s initial plan to reevaluate the substance in June is unlikely to happen,” and “The practical discussion could resume only in the latter half of the year.” The pharmaceutical industry seems to be relieved by the delayed talks on the reimbursement reevaluation. Prior to the outbreak, the industry officials have continuously requested the government to postpone the listed drug reevaluation. In March, the Federation of Korean Industries (FKI) claimed “The listed drug reevaluation should be postponed for a year.” And in April, the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA) again urged the government to “defer the listed drug reimbursement reevaluation.” Currently, Ministry of Food and Drug Safety (MFDS) and Ministry of Health and Welfare (MOHW) are respectively deliberating the choline alfoscerate reevaluation discussions. MFDS is contemplating on whether to remove a part of three approved indications during a Special Reevaluation session after the drug renews its item license. With HIRA, MOHW is considering on reducing reimbursement on some of the drug’s indications or switching the reimbursement type to selective reimbursement. As MOHW has constantly expressed negative stance on providing reimbursement on choline alfoscerate, the ministry would highly likely to reduce reimbursement on some of the three approved indications or to turn the reimbursement type into selective benefit. At the moment, choline alfoscerate has been indicated to treat patients showing secondary symptoms of cerebrovascular insufficiency and degenerative brain-organic psychiatric syndrome— impairment of sense of direction, motivation, judgment and concentration due to confusion and degenerated memory, judgment and motivation; changes in emotions and behaviors—emotionally insecure, hypersensitive to stimulation, and indifferent to surrounding; and senile pseudo-depression.
- Policy
- Chong Kun Dang to enhance Eliquis generic quality
- by Lee, Tak-Sun May 12, 2020 06:27am
- Chong Kun Dang is to enhance quality of Liquisia, a generic version of coagulant medicine Eliquis. Currently leading the Eliquis generic market, Liquisia is aiming for sales expansion through the substance quality improvement. On Apr. 29, Ministry of Food and Drug Safety (MFDS) approved of bioequivalence test plan for Liquisia (apixaban) 5 mg tablet (apixaban). The test would confirm Liquisia’s pharmaceutical absorption rate in healthy adult equal to Eliquis 5 mg tablet. However, Liquisia 5 mg has already passed a bioequivalence test against Eliquis before. The apixaban generic is not even manufactured by a cosigned company. It was approved as a directly manufactured item in March of 2018. The Korean pharmaceutical company has reportedly initiated the latest bioequivalence test project to improve the quality of pharmaceutical substance and manufacturing procedure. The details of the improvement to be made from the existing version have not been revealed, yet. Recently, Chong Kun Dang’s Liquisia sales has skyrocketed. According to the pharmaceutical industry research firm UBIST, the generic’s outpatient prescription volume has reached 395 million won in last first quarter, placing itself on the top among the apixaban generics. Compared to fourth quarter last year, the prescription volume has surged by approximately 80 percent. Although the volume was insignificant against Eliquis generating 12.28 billion won in the same quarter, the industry experts view Chong Kun Dang’s new strategy to expand its new oral anticoagulant (NOAC) generic sales to clinics would work in the end. The company is most likely to strengthen the commercial value and market competitiveness of the generic by enhancing the substance quality. Facing fierce marketing strategies from generics, the original Eliquis maker Bristol-Myers Squibb (BMS) would have to make tighter actions. The multinational pharmaceutical company’s damage would snowball once the currently suspended pricing reduction is executed or the company completely loses in the ongoing patent trial. Fortunately, BMS has successfully protected the initial pricing as Administrative Court, High Court and the Supreme Court accepted the company’s application for an injunction. However, the pricing would be lowered by 30 percent, if the litigation on pricing reduction processed by the High Court is ruled against the company Also, an outcome of the ongoing patent nullification litigation on the original’s pharmaceutical substance could drastically change the market scene. If the Court makes the decision to nullify the patent, already-approved 20 to 30 generics would be launched shortly, dodging the patent infringement issue. The Korean industry would keep a close eye on the apixaban market as it has opened the first door to the NOAC market for Korean companies.
- Company
- Teva gave Celltrion ₩200 billion in copyright deposit
- by An, Kyung-Jin May 12, 2020 06:27am
- 허쥬마(왼쪽)와 트룩시마 제품사진 Celltrion group surpassed the exclusive rights of the two biosimilars in North America, and it was found that it generated a technology fee of nearly ₩200 billion. In a report submitted to the Securities and Exchange Commission (SEC) on the 7th (local time), multinational pharmaceutical company Teva revealed the history of a biosimilar copyright agreement signed with Celltrion Healthcare in the past. According to the report, the company confirmed that in October 2016, it paid out $160 million to Celltrion Healthcare under the condition of exclusive supply of 'Truxima' and 'Herzuma' in the United States and Canada. At the time, both products were subject to a condition of being refundable for $60 million of the down payment because they were prior to obtaining official approval. At present, both 'Truxima' and 'Herzuma' have been approved by the FDA and Health Canada, and their condition has expired when they start selling products. This is the first time that Celltrion Healthcare has revealed the amount of license revenue received from handing over biosimilars' exclusive overseas distribution rights. Celltrion Healthcare was an unlisted company when it signed an agreement with Teva, and did not disclose details of the contract. In the business report submitted to the Financial Supervisory Service by Celltrion Healthcare, only the timing of the contract (October 4, 2016) and distribution countries (USA, Canada, Puerto Rico) were mentioned for the 'Truxima' and 'Herzuma' supply contract' with Teva. The main thing to note in this contract is the size of the down payment. The $160 million secured by Celltrion Healthcare is the third largest among technology transfer contracts signed by domestic pharmaceutical bio companies. In 2015, three types of diabetic new drugs, which Hanmi exported to Sanofi, received the largest contract amount of €204 million. Hanmi's long-lasting obesity diabetes treatment drug ($105 million) was handed over to Janssen for the second largest down payment. SK Biopharmaceuticals signed a technology transfer contract with Able Therapeutics of Switzerland in February last year for a new drug candidate for encephalopathy, 'Cenobamate'. 'Truxima' is a biosimilar product of 'Mabthera' (Rituximab), a flagship product of multinational pharmaceutical company Roche. Mabthera is prescribed for autoimmune diseases such as rheumatoid arthritis, including blood cancer. In the U.S. alone, it is forming a market of about ₩5 trillion (based on 2018 IQVIA). Celltrion Healthcare and Teva were approved for FDA sales of Truxima in November 2018, and launched in the U.S. market starting in November 2019. In February this year, the product was launched in Canada. 'Herzuma' is a biosimilar product of Roche's anti-cancer drug 'Herceptin' (Trastuzumab), which is prescribed for breast cancer, stomach cancer, etc. Herzuma was approved by the FDA in December 2018, and began selling in the US in March this year. In Canada, it was released in January this year. Under the agreement, Teva and Celltrion Healthcare share revenue from product sales in the United States and Canada. An official of Celltrion Healthcare said, "The $ 160 million that Teva released was a pre-paid deposit when it signed a biosimilar license transfer agreement in October 2016. There was a provision that Teva would refund $ 60 million if it did not get FDA approval." "There is no obligation to return when we start selling locally." "Other details cannot be mentioned at a public expense," he said.
- Policy
- Ongentys will be reimbursed upon accepting the committee
- by Lee, Hye-Kyung May 12, 2020 06:27am
- SK Chemicals' new drug 'Ongentys (Opicapone)', which is a new treatment for Parkinson's disease, ,accepts below the evaluation amount of the Pharmaceutical Benefits Advisory Committee the reimbursed price will likely pass. The HIRA (President Seon-min Kim) released the results of the deliberation on the adequacy of the medical care benefits of the decision-making drug that was deliberated by the 5th Pharmaceutical Benefits Advisory Committee on the 8th. The only drug that has been evaluated for reimbursed adequacy at this time is MSD Korea's CMV infection treatment, 'Prevymis (Letermovir) 250mg and 480mg'. Prevymis, a drug that prevents giant cell virus infection in hematopoietic stem cell transplant patients, has been approved for use in the prevention of CMV infection and disease in adult patients who have undergone allogeneic hematopoietic stem cell transplant (HSCT) from the MFDS in 2018. The U.S. permit was in 2017, and the FDA has also designated Prevymis as a breakthrough therapy, a priority review drug, and a fast track drug. Ongentys 50mg deliberated by the committee and the ovarian stimulant 'Rekovelle Prefilled Pen (Follitropin delta)', which is a controlled ovarian stimulant in women receiving supplementary reproductive therapy from Ferring Pharmaceuticals, has a reasonable reimbursement, but the amount requested by the pharmaceutical company is high. Ongentys is a standard treatment for Levodopa/Dopa decarboxylase inhibitor (DDCI), and is an adjunct to Levodopa/Dopa decarboxylase inhibitor (DDCI) in patients with Parkinson's syndrome with symptoms of motor agitation, which do not improve symptoms. It was approved in Korea on November 26, last year. Rekovelle Prefilled Pen received domestic approval as an indication for controlled ovarian stimulation to mature multiple follicles in women receiving adjuvant reproductive procedures, such as in vitro fertilization or intracellular sperm injection, on December 27 last year. The HIRA said that Ongentys and Rekovelle Prefilled Pen are recognized for the appropriateness of the reimbursement when they are accepted below the evaluation amount. However, if the pharmaceutical company does not accept it, non-reimbursement price will be continued. On the other hand, in accordance with Article 11-2 of the Rules on the Regulation for Criteria for Providing Reimbursed services in the NHI, the HIRA evaluates the adequacy of pharmaceuticals through the deliberation of the Pharmaceutical Benefits Advisory Committee. The final evaluation result can be changed if changes in details of the scope of the drug and the standard items of the drug, changes in the permission of the item requested for decision, and withdrawal of the permission.
- Company
- Samsung Biologics, ranked No.1 in the market cap
- by An, Kyung-Jin May 11, 2020 06:19am
- Samsung Biologics (left) & Celltrion headquarters Samsung Biologics is taking third place in the market capitalization of KOSPI with the reflex profit of COVID-19. Difference in market capitalization with Celltrion is about ₩10 trillion, and it has been holding a position as a bio leading stock for 7 months. According to the Korea Exchange on the 8th, Samsung Biologics closed the transaction at ₩588,000, up 3.6% from the previous trading day. Compared to last year's closing price of ₩433,000, the stock price jumped 71.6% in five months. Celltrion's closing price on this day was ₩21,500, up 3.2% from the previous trading day. Although it increased 16.3% from the closing price last year, it did not significantly exceed Samsung Biologics' share price growth during the same period. Changes in market cap of Samsung Bioepis & Celltrion (Unit: ₩100 million, Source: the Korea Exchange) As of 8th, Samsung Biologics' market capitalization is ₩38.90 trillion, ranking third in the KOSPI market. It surpassed Celltrion's market capitalization of ₩28.36 trillion by more than ₩10 trillion, recording the largest market capitalization among pharmaceutical bios. Samsung Biologics' market ranking dropped to 12th place in May last year due to the prosecution investigation by suspicion of fraudulent accounting. However, after the third quarter of last year, the share price turned to a recovery, reflecting good earnings and expectations for growth of subsidiary Samsung Bioepis. Prospects that demand for contract manufacturing organization (CMO) will increase with the spread of COVID-19 this year increased market cap. After signing a CMO contract worth $360 million with Vir Biotechnology in the US last month, as the possibility of market reorganization was raised with regard to additional contract manufacturing organization (CMO) for COVID-19 treatment, it served as a trigger for the share price rise. Samsung Biologics completed the technology transfer process with Vir Biotechnology this year and will start production next year. It is said that the CMO work has been addressed at the 3rd plant, which resolved the concerns about utilization rates raised by some people. On the 10th of last month, when the contract was signed with Vir, Samsung Biologics' market capitalization jumped to more than ₩500 million a day, at ₩3.7 billion. Since then, the market cap continues to rise, and the market capitalization approaches ₩40 trillion at its peak. During the same period, Celltrion's market cap fell slightly from ₩27.17 trillion to ₩26.89 trillion (₩128.3 billion), and the gap with Samsung Biologics widened by more than ₩10 trillion. At the end of last year, Celltrion's market capitalization rose by more than ₩5 trillion over the past five months from ₩23.23 trillion to ₩28.36 trillion. Celltrion, like Samsung Biologics, is on the rise following the COVID-19 crisis, but its growth is far less than that of Samsung Biologics, and falls short of a bio leading stock. The securities firm predicts that this year, the two companies will have the highest performance ever. FnGuide, a financial information company, predicted that Celltrion would record an operating profit (stock price estimate average) of ₩569 billion, up 58.1% from the previous year based on separate financial statements. It is predicted that Samsung Biologics will increase operating profit by ₩228.4 billion, an increase of 149.1%.
